3-(3-bromo-2-methylphenyl)-8-fluoroquinazolin-4(3H)-one | 1231891-13-6

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二氮杂萘
• 英文名称: 3-(3-bromo-2-methylphenyl)-8-fluoroquinazolin-4(3H)-one
• 英文别名: 3-(3-Bromo-2-methylphenyl)-8-fluoroquinazolin-4-one；3-(3-bromo-2-methylphenyl)-8-fluoroquinazolin-4-one
• CAS: 1231891-13-6
• 化学式: C₁₅H₁₀BrFN₂O
• 分子量: 333.16
• InChiKey: MHIXAZKAVSKGLF-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.6
• 重原子数：
  20
• 可旋转键数：
  1
• 环数：
  3.0
• sp3杂化的碳原子比例：
  0.07
• 拓扑面积：
  32.7
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  3-(3-bromo-2-methylphenyl)-8-fluoroquinazolin-4(3H)-one 在 potassium phosphate 、 四(三苯基膦)钯 、 1,1'-双(二苯膦基)二茂铁二氯化钯(II)二氯甲烷复合物 、 potassium acetate 作用下， 以 1,4-二氧六环 、 乙醇 、 水 、 甲苯 为溶剂， 反应 1.0h， 生成 4-(3-(8-fluoro-4-oxoquinazolin-3(4H)-yl)-2-methylphenyl)-7-(2-hydroxypropan-2-yl)-9H-carbazole-1-carboxamide
  参考文献：
  名称：

  Small Molecule Reversible Inhibitors of Bruton’s Tyrosine Kinase (BTK): Structure–Activity Relationships Leading to the Identification of 7-(2-Hydroxypropan-2-yl)-4-[2-methyl-3-(4-oxo-3,4-dihydroquinazolin-3-yl)phenyl]-9H-carbazole-1-carboxamide (BMS-935177)

  摘要：

  Bruton's tyrosine,kinase (BTK) belongs to the TEC family of nonreceptor tyrosine kinases and plays a critical role in multiple cell types responsible for numerous auto-immune diseases. This article will detail the structure-activity relationships (SARs) leading to a novel second generation series of potent and, selective reversible carbazole inhibitors of BTK. With an excellent pharmacokinetic profile as well as demonstrated in vivo activity and an acceptable safety profile, 7-(2-hydroxypropan-2-yl)-4-[2-methyl-3-(4-oXo-3,4-dihydroquinazdlin-3-yl)phenyl]-9H-carbazole-1-carboxarnide 6 (BMS-935177) was selected:to advance into clinical development.

  DOI：

  10.1021/acs.jmedchem.6b00722
• 作为产物：
  描述：

  3-溴-2-甲基苯胺 、 2-氨基-3-氟苯甲酸 、 原甲酸三乙酯 以 甲苯 为溶剂， 反应 16.0h， 生成 3-(3-bromo-2-methylphenyl)-8-fluoroquinazolin-4(3H)-one
  参考文献：
  名称：

  Small Molecule Reversible Inhibitors of Bruton’s Tyrosine Kinase (BTK): Structure–Activity Relationships Leading to the Identification of 7-(2-Hydroxypropan-2-yl)-4-[2-methyl-3-(4-oxo-3,4-dihydroquinazolin-3-yl)phenyl]-9H-carbazole-1-carboxamide (BMS-935177)

  摘要：

  Bruton's tyrosine,kinase (BTK) belongs to the TEC family of nonreceptor tyrosine kinases and plays a critical role in multiple cell types responsible for numerous auto-immune diseases. This article will detail the structure-activity relationships (SARs) leading to a novel second generation series of potent and, selective reversible carbazole inhibitors of BTK. With an excellent pharmacokinetic profile as well as demonstrated in vivo activity and an acceptable safety profile, 7-(2-hydroxypropan-2-yl)-4-[2-methyl-3-(4-oXo-3,4-dihydroquinazdlin-3-yl)phenyl]-9H-carbazole-1-carboxarnide 6 (BMS-935177) was selected:to advance into clinical development.

  DOI：

  10.1021/acs.jmedchem.6b00722

文献信息

• Small Molecule Reversible Inhibitors of Bruton’s Tyrosine Kinase (BTK): Structure–Activity Relationships Leading to the Identification of 7-(2-Hydroxypropan-2-yl)-4-[2-methyl-3-(4-oxo-3,4-dihydroquinazolin-3-yl)phenyl]-9<i>H</i>-carbazole-1-carboxamide (BMS-935177)
  作者：George V. De Lucca、Qing Shi、Qingjie Liu、Douglas G. Batt、Myra Beaudoin Bertrand、Rick Rampulla、Arvind Mathur、Lorell Discenza、Celia D’Arienzo、Jun Dai、Mary Obermeier、Rodney Vickery、Yingru Zhang、Zheng Yang、Punit Marathe、Andrew J. Tebben、Jodi K. Muckelbauer、ChiehYing J. Chang、Huiping Zhang、Kathleen Gillooly、Tracy Taylor、Mark A. Pattoli、Stacey Skala、Daniel W. Kukral、Kim W. McIntyre、Luisa Salter-Cid、Aberra Fura、James R. Burke、Joel C. Barrish、Percy H. Carter、Joseph A. Tino

  DOI：10.1021/acs.jmedchem.6b00722

  日期：2016.9.8

  Bruton's tyrosine,kinase (BTK) belongs to the TEC family of nonreceptor tyrosine kinases and plays a critical role in multiple cell types responsible for numerous auto-immune diseases. This article will detail the structure-activity relationships (SARs) leading to a novel second generation series of potent and, selective reversible carbazole inhibitors of BTK. With an excellent pharmacokinetic profile as well as demonstrated in vivo activity and an acceptable safety profile, 7-(2-hydroxypropan-2-yl)-4-[2-methyl-3-(4-oXo-3,4-dihydroquinazdlin-3-yl)phenyl]-9H-carbazole-1-carboxarnide 6 (BMS-935177) was selected:to advance into clinical development.